Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
The Obama Administration is holding off from publishing new hospital-quality ratings over concerns raised by healthcare providers and Congress over the methodology of the ratings system, the Wall Street Journal reports.
The Centers for Medicare and Medicaid Services were slated to begin publishing start-ratings for hospitals to help patients compare the quality of service at the facilities, but the date for the release has been pushed back to July, according to federal officials. Read more
Medtronic today released 1-year results from a study of patients who experienced a cryptogenic stroke, claiming that its Reveal Linq insertable cardiac monitor was able to detect atrial fibrillation at a greater rate than previously reported in a 2014 clinical trial.
Results from the real-world study were presented at the 68th American Academy of Neurology’s annual meeting in Vancouver, Canada. Read more
Stryker said today it closed its buy of CareFusion‘s vertebral compression fracture portfolio from Becton Dickinson & Co. in an all-cash transaction and released a street-beating 1st quarter earnings report.
The purchased portfolio is comprised of minimally-invasive systems used in vertebroplasty and vertebral augmentation procedures, which BD purchased as part of CareFusion’s portfolio in March 2015. Read more
Medtronic said today it is initiating a voluntary recall of battery packs used with its Covidien Oridion labeled Capnostream 20 and 20p patient monitors due to a defect causing an increased risk of thermal damage in the packs.
Capnostream monitors are external devices used to assess respiratory status and identify changes in breathing, the Fridley, Minn.-based company said, and are used in both clinical and home settings. Read more
1. FDA: TransEnterix Surgibot 510(k) does not meet criteria for “substantial equivalence”, shares plummet
TransEnterix said that the FDA responded to the 510(k) application for its robotic surgery SurgiBot system, saying that the platform does not meet the criteria for substantial equivalence based on the data and information in the application.
Research Triangle Park, N.C.-based TransEnterix claims SurgiBot as the 1st patient-side robotically enhanced laparoscopy platform, designed to be wheeled to a patient’s bedside and operate through a single port. Read more